natgillin/translations-raw huggingface dataset:
In case of accidental self-ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 
Kod neželjenog gutanja odmah potražite liječnički savjet i pokažite liječniku uputu o VMP ili etiketu.
- very common (more than 1 in 10 animals treated displaying adverse reaction(s) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports) 
- česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja)
Fluoxetine is metabolised to norfluoxetine, an equipotent SSRI that contributes to the efficacy of the veterinary medicinal product. 
Fluoksetin se metabolizira u norfluoksetin, ekvipotentni selektivni inhibitor serotonina koji doprinosi djelotvornosti veterinarsko-medicinskog proizvoda.
White high density polyethylene (HDPE) bottle with a child resistant closure, cotton colier and a desiccant canister. 
Bijela boca od polietilena velike gustoće (HDPE) sa čepom kojeg djeca na mogu otvoriti, pamučnom zaštitom i spremnikom sa sredstvom za sušenje.
Though rare, seizures may occur in dogs treated with Reconcile. 
Iako rijetko, kod pasa liječenih Reconcile-om može doći do napadaja.
Pharmacotherapeutic group: selective serotonin reuptake inhibitors (SSRI) ATCvet code: QNO6ABO3 
Farmakoterapijska grupa: selektivni inhibitori serotonina (SSRl).
Though rare, seizures may occur in dogs treated with the product. 
Iako rijetko, kod pasa liječenih proizvodom može doći do napadaja.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Outer carton 8mg, 16 mg, 32 mg and 64 mg 
PODACI NA VANJSKOM PAKOVANJU { Vanjski karton 8 mg, 16 mg, 32 mg i 64 mg }
After administration, fluoxetine readily appeared in plasma with mean Tmax values ranging from 1.25 to 1.75 hours on day 1 and from 2.5 to 2.75 hours on day 21. 
Nakon primjene, fluoksetin je bio prisutan u plazmi s vrijednostima Tmax od 1,25 do 1,75 sati na dan 1 i od 2,5 do 2,75 sati na dan 21. Razine u plazmi su se smanjile s vrijednostima t½ od 4,6 do 5,7 sati na dan 1 i od 5,1 do 10,1 sati na 21dan.
Shelf-life after first opening the container: 30 days. 
Rok trajanja nakon otvaranja boce: 30 dana.
Do not use in case of hypersensitivity to fluoxetine or other Selective Serotonin Re-Uptake Inhibitors (SSRIs) or to any of the excipients. 
Ne primjenjivati u slučaju preosjetljivosti na fluoksetin ili druge selektivne inhibitore serotonina (SSRI)
Any unused product or waste material should be disposed of in accordance with local requirements. 
Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijal dobiveni primjenom tih proizvoda mora se odlagati u skladu sa lokalnim propisima.
Norfluoxetine plasma levels slowly appeared in plasma and were slowly eliminated with t½ values ranging from 44.2 to 48.9 hours on day 21. 
Razine norfluoksetina su se polako pojavljivale u plazmi i polako se eliminirale s vrijednostima t½ od 44,2 do 48,9 na dan 21. Norfluoksetin Cmax i PIK bili su općenito proporcionalni s dozama, no ove su vrijednosti bile za trostruko do četverostruko više na dan 21 nego na dan 1.
Oral use. 
ili pomoćne tvari.
Do not store above 30°C. 
11. POSEBNI UVJETI ČUVANJA Ne čuvati iznad 30°C.
Special warnings for each target species: 
Posebna upozorenja za primjenu na životinjama:
Reconcile 64 mg tablets: 4209 
Reconcile 64 mg: 4209
Reconcile 32 mg tablets: 4207 
Reconcile 32 mg: 4207
Reconcile 8 mg tablets: 4203 
Reconcile 8 mg: 4203
Reconcile 16 mg tablets: 4205 
Reconcile 16 mg: 4205
Reconcile 8 mg tablet Reconcile 16 mg tablet Reconcile 32 mg tablet Reconcile 64 mg tablet 
Tableta Reconcile 8 mg Tableta Reconcile 16 mg Tableta Reconcile 32 mg Tableta Reconcile 64 mg
Reconcile 8mg tablet Reconcile 16mg tablet Reconcile 32mg tablet Reconcile 64mg tablet 
Reconcile tableta 8 mg Reconcile tableta 16 mg Reconcile tableta 32 mg Reconcile tableta 64 mg
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated ) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports 
Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e) ) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja)
8 mg fluoxetine (as 9.04 mg fluoxetine hydrochloride) 16mg fluoxetine (as 18.08mg fluoxetine hydrochloride) 32 mg fluoxetine (as 36.16 mg fluoxetine hydrochloride) 64 mg fluoxetine (as 72.34 mg fluoxetine hydrochloride) 
8 mg fluoksetina (kao 9,04 mg fluoksetin-hidroklorid) 16 mg fluoksetina (kao 18,08 mg fluoksetin-hidroklorida) 32 mg fluoksetina (kao 36,16 mg fluoksetin-hidroklorida) 64 mg fluoksetina (kao 72,34 mg fluoksetin-hidroklorida)
Reconcile 8 mg: Fluoxetine 8 mg (equivalent to 9.04 mg fluoxetine hydrochloride) Reconcile 16mg: Fluoxetine 16 mg (equivalent to 18.08mg fluoxetine hydrochloride) Reconcile 32 mg: Fluoxetine 32 mg (equivalent to 36.16 mg fluoxetine hydrochloride) Reconcile 64 mg: Fluoxetine 64 mg (equivalent to 72.34 mg fluoxetine hydrochloride) 
Reconcile 8 mg: Fluoksetin 8 mg (odgovara 9,04 mg fluoksetin-hidroklorida) Reconcile 16 mg: Fluoksetin 16 mg (odgovara 18,08 mg fluoksetin-hidroklorida) Reconcile 32 mg: Fluoksetin 32 mg (odgovara 36,16 mg fluoksetin-hidroklorida) Reconcile 64 mg: Fluoksetin 64 mg (odgovara 72,34 mg fluoksetin-hidroklorida)
Microcrystalline cellulose Sucrose (as compressible sugar ) Crospovidone 
Sukroza (kao komprimirani šećer)
Reconcile 8 mg: fluoxetine 8 mg (equivalent to 9.04 mg fluoxetine hydrochloride) Reconcile 16mg: fluoxetine 16 mg (equivalent to 18.08mg fluoxetine hydrochloride) Reconcile 32 mg: fluoxetine 32 mg (equivalent to 36.16 mg fluoxetine hydrochloride) 
Reconcile 8 mg: fluoksetin 8 mg (odgovara 9,04 mg fluoksetin-hidroklorida) Reconcile 16 mg: fluoksetin 16 mg (odgovara 18,08 mg fluoksetin-hidroklorida)
Reconcile 8 mg chewable tablets for dogs Reconcile 16 mg chewable tablets for dogs Reconcile 32 mg chewable tablets for dogs Reconcile 64 mg chewable tablets for dogs fluoxetine 
Tablete za žvakanje za pse Reconcile 8 mg Tablete za žvakanje za pse Reconcile 16 mg Tablete za žvakanje za pse Reconcile 32 mg Tablete za žvakanje za pse Reconcile 64 mg fluoksetin
Reconcile 8 mg chewable tablets for dogs Reconcile 16 mg chewable tablets for dogs Reconcile 32 mg chewable tablets for dogs Reconcile 64 mg chewable tablets for dogs 
Tablete za žvakanje za pse Reconcile 8 mg Tablete za žvakanje za pse Reconcile 16 mg Tablete za žvakanje za pse Reconcile 32 mg Tablete za žvakanje za pse Reconcile 64 mg
Reconcile 64 mg: fluoxetine 64 mg (equivalent to 72.34 mg fluoxetine hydrochloride) 
Reconcile 32 mg: fluoksetin 32 mg (odgovara 36,16 mg fluoksetin-hidroklorida) Reconcile 64 mg: fluoksetin 64 mg (odgovara 72,34 mg fluoksetin-hidroklorida)
Tell your doctor or pharmacist if you are taking , have recently taken or might take any other medicines. 
Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti bilo koje druge lijekove.
What Paglitaz is and what it is used for 
Što je Paglitaz i za što se koristi
Date of first authorisation: 21 March 2012 Date of latest renewal: 
Datum prvog odobrenja: 21. ožujka 2012.
Paglitaz with food and drink You may take your tablets with or without food. 
Paglitaz s hranom i pićem Tablete možete uzimati s hranom ili bez nje.
Your doctor will check whether Paglitaz is working 3 to 6 months after you start taking it. 
Liječnik će provjeriti djelovanje lijeka Paglitaz 3 do 6 mjeseci nakon što ga počnete uzimati.
Paglitaz helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces. 
Paglitaz pridonosi kontroli razine šećera u krvi kad imate šećernu bolest tipa 2, tako što pomaže Vašem tijelu da bolje iskoristi inzulin koji stvara.
Before you start taking Paglitaz you will have a blood sample taken to check your liver function. 
Prije nego što počnete uzimati Paglitaz uzet će Vam se uzorak krvi da bi se provjerila funkcija jetre.
If you have the impression that the effect of Paglitaz is too weak, talk to your doctor. 
Ako imate dojam da je učinak lijeka Paglitaz preslab, razgovarajte o tome sa svojim liječnikom.
Do not take Paglitaz: - if you are hypersensitive (allergic) to pioglitazone or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Paglitaz: - ako ste alergični na pioglitazon ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
If you take more Paglitaz than you should 
Ako uzmete više lijeka Paglitaz nego što ste trebali
Other medicines and Paglitaz 
Drugi lijekovi i Paglitaz
If you take Paglitaz with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia). 
Ako uzimate Paglitaz s drugim lijekovima za šećernu bolest, veća je vjerojatnost da Vam šećer u krvi padne ispod normalne razine (hipoglikemija).
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.Your doctor will advise you to discontinue this medicine. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete ovaj lijek.
What you need to know before you take Paglitaz 
Što morate znati prije nego počnete uzimati Paglitaz
If you stop using Paglitaz tablets, your blood sugar may go up. 
Ako prestanete uzimati Paglitaz, šećer u krvi Vam se može povisiti.
What Paglitaz is and what it is used for What you need to know before you take Paglitaz How to take Paglitaz 
Što se nalazi u ovoj uputi Što je Paglitaz i za što se koristi Što morate znati prije nego počnete uzimati Paglitaz Kako uzimati Paglitaz
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Paglitaz. 
Ako Vam je liječnik rekao da ne podnosite neke šećere, obratite se liječniku prije nego što uzmete Paglitaz.
Take Paglitaz tablets daily as prescribed. 
Uzimajte Paglitaz svaki dan, onako kako je propisano.
If you are following a diabetic diet, you should continue with this while you are taking Paglitaz. 
Ako se pridržavate dijabetičke dijete, trebate nastaviti s dijetom dok uzimate Paglitaz.
The other side effects that have been experienced by some patients when Paglitaz is taken with other antidiabetic medicines are: 
Druge nuspojave koje su neki bolesnici osjetili kod uzimanja lijeka Paglitaz s drugim antidijabetičkim lijekovima su:
Pioglitazone is indicated as second or third line in the treatment of type 2 diabetes mellitus as described below: 
Pioglitazon je indiciran kao druga ili treća linija liječenja šećerne bolesti tipa 2 na sljedeći način:
Paglitaz may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control in blood sugar. 
Paglitaz se može primjenjivati sam u bolesnika koji ne mogu uzimati metformin, a u kojih se liječenjem dijetom i tjelovježbom nije uspjela postići kontrola šećera u krvi ili se može dodati drugim lijekovima (kao što su metformin, sulfonilureja ili inzulin) koji nisu uspjeli osigurati dostatnu kontrolu šećera u krvi.
When Paglitaz is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines. 
Kad se Paglitaz uzima zajedno s drugim lijekovima za liječenje šećerne bolesti (kao što su inzulin, klorpropamid, glibenklamid, gliklazid, tolbutamid) liječnik će Vam reći trebate li te lijekove uzimati u manjim dozama.
What Paglitaz contains - The active substance is pioglitazone. 
Što Paglitaz sadrži - Djelatna tvar je pioglitazon.
Paglitaz contains pioglitazone. 
Paglitaz sadrži pioglitazon.
Your blood sugar will be checked, and your dose of Paglitaz may need to be changed. 
Provjerit će Vam šećer u krvi i nakon toga možda promijeniti dozu lijeka Paglitaz.
If you stop taking Paglitaz 
Ako prestanete uzimati Paglitaz
The risk of fractures should be considered in the long term care of patients treated with pioglitazone. 
Rizik od prijeloma treba uzeti u obzir kod dugotrajnog liječenja bolesnika pioglitazonom.
Some epidemiological studies have suggested a similarly increased risk of fracture in both men and women. 
Neka epidemiološka ispitivanja sugeriraju na jednako povećani rizik od lomova i u muškaraca i u žena.
If you accidentally take too many Paglitaz tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. 
Ako slučajno uzmete previše tableta ili ako neka druga osoba ili dijete uzmu
Paglitaz contains lactose monohydrate 
Paglitaz sadrži laktozu hidrat
If you forget to take Paglitaz 
Ako ste zaboravili uzeti Paglitaz
Paglitaz tablets should be used every day to work properly. 
Da bi Paglitaz ispravno djelovao, treba ga uzimati svaki dan.
Environmental Risk Assessment (ERA) : no environmental impact is anticipated from the clinical use of pioglitazone. 
Procjena rizika za okoliš (ERA): ne očekuje se utjecaj na okoliš tijekom kliničke primjene pioglitazona.
Paglitaz tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. 
Paglitaz tablete sadrže laktozu hidrat te se stoga ne smiju primjenjivati u bolesnika s rijetkim nasljednim poremećajima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcijom glukoze-galaktoze.
Talk to your doctor before taking Paglitaz: - if you retain water (fluid retention) or have heart failure problems in particular if you are over 
Obratite se svom liječniku prije nego uzmete Paglitaz: - ako zadržavate vodu (nakupljanje tekućine) ili imate tegobe s zatajivanjem srca, osobito ako ste stariji od 75 godina.
How to take Paglitaz 
Kako uzimati Paglitaz
Localised swelling (oedema) has also been experienced very commonly in patients taking Paglitaz in combination with insulin. 
Lokalizirano oteknuće (edemi) također su vrlo često nastajali u bolesnika koji su uzimali Paglitaz u kombinaciji s inzulinom.
as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. 
kao trojna peroralna terapija u kombinaciji sa - metforminom i sulfonilurejom, u odraslih bolesnika (osobito bolesnika s prekomjernom tjelesnom težinom) s nedostatnom kontrolom glikemije usprkos dvojnoj peroralnoj terapiji.
as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin; - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea; 
kao dvojna peroralna terapija u kombinaciji sa - metforminom, u odraslih bolesnika (osobito bolesnika s prekomjernom tjelesnom težinom) s nedostatnom kontrolom glikemije usprkos monoterapiji metforminom u najvećoj podnošljivoj dozi - sulfonilurejom, samo u odraslih bolesnika s nepodnošenjem metformina ili u kojih je metformin kontraindiciran, s nedostatnom kontrolom glikemije usprkos monoterapiji sulfonilurejom u najvećoj podnošljivoj dozi.
You can usually continue to take other medicines whilst you are being treated with Paglitaz. 
Za vrijeme liječenja lijekom Paglitaz obično možete nastaviti uzimati druge lijekove.
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥65 years compared to 4.0% in patients less than 65 years. 
U bolesnika na inzulinu bez pioglitazona, incidencija srčanog zatajenja bila je 8,2% u osoba u dobi ≥65 godina, u odnosu na 4,0% u bolesnika mlađih od 65 godina.
Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs, including selective COX-2 inhibitors. 
Nakon stavljanja lijeka u promet prijavljeni su slučajevi perifernih edema i zatajenja srca u bolesnika koji su istodobno uzimali pioglitazon s nesteroidnim protuupalnim lijekovima, uključujući i selektivne COX-2 inhibitore.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Paglitaz and insulin experienced the development of heart failure. 
U nekih bolesnika koji su dugo imali šećernu bolest tipa 2 i srčanu bolest ili su preboljeli moždani udar a liječili su se lijekom Paglitaz i inzulinom došlo je do zatajenja srca.
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Paglitaz. 
Karcinom mokraćnog mjehura manje je često (mogu se javiti u do 1 na 100 osoba) nastao u bolesnika koji uzimaju Paglitaz.
In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged ≥65 years compared with those less than 65 years (9.7% compared to 4.0%). 
U ovom ispitivanju, u bolesnika koji su primali pioglitazon i inzulin, zabilježen je veći postotak bolesnika sa zatajenjem srca u skupini bolesnika u dobi od ≥65 godina u odnosu na one mlađe od 65 godina (9,7% u odnosu na 4,0%).
Broken bones have been reported commonly (may affect up to 1 in 10 people) in women patients taking Paglitaz. 
Prijelomi kostiju često (mogu se javiti u do 1 na 10 osoba) su zabilježeni u žena koje su uzimale Paglitaz.
14 tablets: EU/1/11/721/015 28 tablets: EU/1/11/721/016 30 tablets: EU/1/11/721/017 56 tablets: EU/1/11/721/018 60 tablets: EU/1/11/721/019 90 tablets: EU/1/11/721/020 98 tablets: EU/1/11/721/021 
14 tableta: EU/1/11/721/015 28 tableta: EU/1/11/721/016 30 tableta: EU/1/11/721/017 56 tableta: EU/1/11/721/018 60 tableta: EU/1/11/721/019 90 tableta: EU/1/11/721/020 98 tableta: EU/1/11/721/021
14 tablets: EU/1/11/721/001 28 tablets: EU/1/11/721/002 30 tablets: EU/1/11/721/003 56 tablets: EU/1/11/721/004 60 tablets: EU/1/11/721/005 90 tablets: EU/1/11/721/006 98 tablets: EU/1/11/721/007 
14 tableta: EU/1/11/721/001 28 tableta: EU/1/11/721/002 30 tableta: EU/1/11/721/003 56 tableta: EU/1/11/721/004 60 tableta: EU/1/11/721/005 90 tableta: EU/1/11/721/006 98 tableta: EU/1/11/721/007
What Paglitaz looks like and contents of the pack White to almost white round tablets with bevelled edges (diameter 8.0 mm). 
Kako Paglitaz izgleda i sadržaj pakiranja Bijele do gotovo bijele, okrugle tablete ukošenih rubova (promjer 8,0 mm).
14 tablets: EU/1/11/721/008 28 tablets: EU/1/11/721/009 30 tablets: EU/1/11/721/010 56 tablets: EU/1/11/721/011 60 tablets: EU/1/11/721/012 90 tablets: EU/1/11/721/013 98 tablets: EU/1/11/721/014 
14 tableta: EU/1/11/721/008 28 tableta: EU/1/11/721/009 30 tableta: EU/1/11/721/010 56 tableta: EU/1/11/721/011 60 tableta: EU/1/11/721/012 90 tableta: EU/1/11/721/013 98 tableta: EU/1/11/721/014
Combination with sulphonylurea with metformin and sulphonylurea with insulin 
Kombinacija s metforminom sa sulfonilurejom s metforminom i sulfonilurejom s inzulinom
How to store Paglitaz 
Kako čuvati Paglitaz
Your doctor will ask you to have blood tests periodically during treatment with Paglitaz. 
Liječnik će tražiti da za vrijeme liječenja lijekom Paglitaz povremeno napravite krvne pretrage, da bi se provjerilo radi li Vaša jetra normalno.
There may be an increased possibility of your becoming pregnant because you may ovulate again when you take Paglitaz. 
Kad uzimate Paglitaz, možete ponovno imati ovulaciju pa mogućnost trudnoće može biti povećana.
Allergic reactions have been reported (frequency not known) in patients taking Paglitaz. 
U bolesnika koji su uzimali Paglitaz prijavljene su alergijske reakcije (nepoznate učestalosti).
Blurred vision due to swelling (or fluid) at the back of the eye (frequency not known) has also been reported in patients taking Paglitaz. 
U bolesnika koji uzimaju Paglitaz zabilježen je i zamagljen vid zbog oticanja (ili tekućine) stražnje strane oka (nepoznata učestalost).
Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. 
Nakon stavljanja lijeka na tržište, u bolesnika koji su liječeni pioglitazonom prijavljeni su slučajevi reakcija preosjetljivosti.
If you experience this symptom for the first time, talk to your 
Ako prvi put osjetite ovaj simptom, čim prije razgovarajte s Vašim liječnikom.
Paglitaz 30 mg tablets 
Paglitaz 30 mg tablete
Paglitaz 45 mg tablets 
Paglitaz 45 mg tablete
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon uncommon uncommon uncommon uncommon Respiratory, thoracic and mediastinal disorders dyspnoea common 
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe) karcinom mokraćnog mjehura manje često manje često manje često manje često manje često
The other side effects that have been experienced by some patients taking Paglitaz are: 
Ostale nuspojave koje su osjetili neki bolesnici koji uzimaju
Paglitaz 45 mg tablets Pioglitazone 
Paglitaz 45 mg tablete pioglitazon
Paglitaz 15 mg tablets 
Paglitaz 15 mg tablete
Paglitaz 15 mg tablets Pioglitazone 
Paglitaz 15 mg tablete pioglitazon
Paglitaz 30 mg tablets Pioglitazone 
Paglitaz 30 mg tablete pioglitazon
Nervous system disorders hypo-aesthesia common common common common common headache common uncommon dizziness common insomnia uncommon uncommon uncommon uncommon uncommon 
Poremećaji živčanog sustava hipoestezija glavobolja često manje često omaglica nesanica manje često manje često manje često manje često manje često
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin visual disturbance common common uncommon macular oedema not known not known not known not known not known 
Poremećaji oka poremećaj vida često manje često makularni edem nepoznato nepoznato nepoznato nepoznato nepoznato
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin oedema very common fatigue uncommon 
Kombinacija s metforminom sa sulfonilurejom s metforminom i sulfonilurejom s inzulinom hipoglikemija manje često vrlo često pojačan apetit manje često
A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA1c ≥ 8.0% after the first six months of 
Kliničko ispitivanje pioglitazona u usporedbi s monoterapijom gliklazidom bilo je produljeno na dvije godine kako bi se procijenilo vrijeme do prestanka odgovora na terapiju (definirano kao nastanak
Heart failure has been experienced commonly (may affect up to 1 in 10 people) in patients taking Paglitaz in combination with insulin. 
U bolesnika koji su uzimali Paglitaz u kombinaciji s inzulinom često (mogu se javiti u do 1 na 10 osoba) se razvilo zatajenje srca.
What Paglitaz looks like and contents of the pack White to almost white round tablets with bevelled edges and with engraved "45" on one side of tablet (diameter 10.0 mm). 
Bijele do gotovo bijele, okrugle tablete ukošenih rubova, s urezanom oznakom ‘45' na jednoj strani tablete (promjer 10,0 mm).